An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

PRIMARY OBJECTIVE: I. To evaluate the accuracy of fluorine F 18 flotufolastat (flotufolastat F 18) compared with prostate biopsy to determine treatment success following focal therapy of the prostate. SECONDARY OBJECTIVE: I. To evaluate the standard uptake volume (SUV) threshold of flotufolastat F 18 compared to Gleason score. EXPLORATORY OBJECTIVE: I. To compare how flotufolastat F 18 and gallium Ga 68 gozetotide (Ga 68 PSMA 11) are distributed within the prostate in men who have previously undergone focal therapy. OUTLINE: Patients receive flotufolastat F-18 intravenously (IV). Then 50-100 minutes after injection, patients undergo whole-body PET/CT over 20-50 minutes. Patients then undergo PET/CT/ultrasound fusion biopsy within 3 months. After completion of study intervention, patients are followed up at 1 month post-biopsy and then every 12 months for up to 10 years.